Dossier assessment
Zuranolone (postpartum depression) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Zuranolone (postpartum depression) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Zuranolone (postpartum depression) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
Adult patients with postpartum depression following childbirth with mild depressive symptoms, or with moderate to severe depressive symptoms
Result of dossier assessment:
Added benefit not proven
Project details
- Project no.
- A26-86
- Commission
- Commission awarded on 14.07.2026 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Mental and emotional wellbeing
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A26-86